My talk presenting my thesis work per invitation of Research and Development Division of Genzyme Corporation to the Lipid Storage Disorders Department. October 5, 2007. Boston, MA: "Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology". My PhD was earned through the Integrated Biomedical Sciences, September 2007, The Ohio State University, College of Medicine Columbus, OH. Area of focus for my PhD: Biochemical and Molecular Disease Mechanisms. Dissertation title: Sphingosine 1-phosphate Receptor Subtype Influence Over Glioblastoma Multiforme Malignant Behavior"
Improved Anti-miRNA (AMOs) and Splice-Switching Oligonucleotides (SSOs), presented by Dr Mark Behlke, Chief Scientific Officer at Integrated DNA Technologies
Improved Anti-miRNA (AMOs) and Splice-Switching Oligonucleotides (SSOs), presented by Dr Mark Behlke, Chief Scientific Officer at Integrated DNA Technologies
The discovery of the nuclear factor TDP-43 involvement in neurodegenerative disease has increased significantly the general interest on the characteristics of this protein. The aberrant localization and aggregation of TDP-43 in affected tissues coupled with the tight auto regulation of TDP 43 cellular levels has suggested novel pathways for neurodegeneration. TDP 43 is predominantly a nuclear protein that shuttles between nucleus and cytoplasm. In disease neurons TDP 43 mislocalize to cytoplasmic inclusions with devastating consequences on neuronal survival. These cytoplasmic aggregation disrupts the TDP-43 control of its own cellular level. In fact autoregulation is mediated byan unusual splicing event in the 3’UTR of its pre mRNA for which is essentiial the presence of TDP 43 in the nucleus. In addition animal models and highthroughput assays have recently highlighted the role played by this protein in the regulation of hundreds of nuclear and cytoplasmic RNA transcripts, many of them belonging to key genes for neuronal metabolism. A model has been developed to study the determinants of the aggregation process and the impact of the latter on neuronal function. Animal models of the disease have been developed in different species mainly mice and flies.
KEY CONCEPTS
18.1 Bacteria often respond to environmental change by
regulating transcription
18.2 Eukaryotic gene expression is regulated at many stages
18.3 Noncoding RNAs play multiple roles in controlling gene
expression
18.4 A program of differential gene expression leads to the different cell types in a multicellular organism
18.5 Cancer results from genetic changes that affect cell cycle control
Do plants contain typical GPCRs?” How is G-protein signaling operating in plants.
G-proteins are universal signal transducers mediating many cellular responses. In animal systems the G-protein signaling cycle is activated by seven transmembrane-spanning G-protein coupled receptors (or GPCRs, popularly known as “serpentine receptors”). Whether typical G protein-coupled receptors (GPCRs) exist in plants or not is a fundamental question. In contrast to the animal system, the existence of these types of receptors in plants still remains controversial. While in animals ligand binding causes a change in receptor conformation that activate a particular G Protein, in plants, such mechanism is unknown. In fact, it is considered that the plants G-Proteins are self-activating. The G Proteins have their respective GPCRs in animal system. A lot of information is already accumulated in animal system and hence the animal GPCRs are considered “canonical.” Thus, from the very beginning, plant G-proteins have been compared with the animal counterparts and studied as an extrapolation of the animal model. This presentation provides an insight into the molecular mechanisms of G Protein activation in plants as well as whether “canonical” GPCRs are present in any plant species or not.
RNA splicing mutations and human disease: Pompe disease - Emanuele Buratti
Convegno del 25 novembre "Diagnosi e management della glicogenosi tipo 2" - Centro di coordinamento regionale malattie rare FVG
El lunes y martes 20 y 21 de noviembre coordinamos un simposio internacional en la Fundación Ramón Areces, sobre los defectos del transporte de aminoácidos.
The discovery of the nuclear factor TDP-43 involvement in neurodegenerative disease has increased significantly the general interest on the characteristics of this protein. The aberrant localization and aggregation of TDP-43 in affected tissues coupled with the tight auto regulation of TDP 43 cellular levels has suggested novel pathways for neurodegeneration. TDP 43 is predominantly a nuclear protein that shuttles between nucleus and cytoplasm. In disease neurons TDP 43 mislocalize to cytoplasmic inclusions with devastating consequences on neuronal survival. These cytoplasmic aggregation disrupts the TDP-43 control of its own cellular level. In fact autoregulation is mediated byan unusual splicing event in the 3’UTR of its pre mRNA for which is essentiial the presence of TDP 43 in the nucleus. In addition animal models and highthroughput assays have recently highlighted the role played by this protein in the regulation of hundreds of nuclear and cytoplasmic RNA transcripts, many of them belonging to key genes for neuronal metabolism. A model has been developed to study the determinants of the aggregation process and the impact of the latter on neuronal function. Animal models of the disease have been developed in different species mainly mice and flies.
KEY CONCEPTS
18.1 Bacteria often respond to environmental change by
regulating transcription
18.2 Eukaryotic gene expression is regulated at many stages
18.3 Noncoding RNAs play multiple roles in controlling gene
expression
18.4 A program of differential gene expression leads to the different cell types in a multicellular organism
18.5 Cancer results from genetic changes that affect cell cycle control
Do plants contain typical GPCRs?” How is G-protein signaling operating in plants.
G-proteins are universal signal transducers mediating many cellular responses. In animal systems the G-protein signaling cycle is activated by seven transmembrane-spanning G-protein coupled receptors (or GPCRs, popularly known as “serpentine receptors”). Whether typical G protein-coupled receptors (GPCRs) exist in plants or not is a fundamental question. In contrast to the animal system, the existence of these types of receptors in plants still remains controversial. While in animals ligand binding causes a change in receptor conformation that activate a particular G Protein, in plants, such mechanism is unknown. In fact, it is considered that the plants G-Proteins are self-activating. The G Proteins have their respective GPCRs in animal system. A lot of information is already accumulated in animal system and hence the animal GPCRs are considered “canonical.” Thus, from the very beginning, plant G-proteins have been compared with the animal counterparts and studied as an extrapolation of the animal model. This presentation provides an insight into the molecular mechanisms of G Protein activation in plants as well as whether “canonical” GPCRs are present in any plant species or not.
RNA splicing mutations and human disease: Pompe disease - Emanuele Buratti
Convegno del 25 novembre "Diagnosi e management della glicogenosi tipo 2" - Centro di coordinamento regionale malattie rare FVG
El lunes y martes 20 y 21 de noviembre coordinamos un simposio internacional en la Fundación Ramón Areces, sobre los defectos del transporte de aminoácidos.
El lunes y martes 20 y 21 de noviembre coordinamos un simposio internacional en la Fundación Ramón Areces, sobre los defectos del transporte de aminoácidos.
Signal transducing machinery as targets for potential drugs.
Drugs:-
a). Diclofenac- for treating cholera toxin
b). Fasentin- for treating insulin signalling
"Stress is Detrimental and Moderate Exercise is Beneficial to Lupus Nephritis...Nicholas Young
Presented this work as a poster tour presentation at The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy. Awarded a travel bursary to attend this conference.
"Oral administration of nano-emulsion curcumin suppresses LPS-induced NFkB si...Nicholas Young
Sildes from a portion of my talk per invitation of the Physiology research group at aTyr Pharma June 1-3, 2014, San Diego, CA. Subsequently, this project has translated to a human clinical trial of this patented anti-inflammatory drug (nanoemulsified curcumin; patented through my collaboration with the Department of Pharmacology at Ohio State).
Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a...Nicholas Young
My talk on muscle auto-antigens in myositis presented at the American College of Rheumatology 79th Meeting during the “Myositis and Myopathies: Novel Insights into Disease Pathogenesis” concurrent abstract oral presentation session. November 4, 2012 in Washington, D.C.
“A Chimeric Human-Mouse Model of Sjögren's Syndrome” Nicholas Young
My talk from The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-28, 2014 in Chicago, IL: “A Chimeric Human-Mouse Model of Sjögren's Syndrome”. Recipient of a travel award given to selected abstracts to attend this conference.
"Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis ...Nicholas Young
My talk from the American College of Rheumatology Meeting in Boston, MA, November 14-19, 2014: • "Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-kB-Mediated Inflammation".
“Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnosti...Nicholas Young
My talk from The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology meeting June 10-13, 2015 in Rome, Italy: • “Manocept, a derivative of FDA-approved 99mTc-Tilmanocept, exhibits diagnostic potential by specifically identifying macrophages in rheumatoid arthritis: a novel application of an existing drug”. Awarded a travel bursary to attend this conference.
“Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ...Nicholas Young
My talk at The Federation of Clinical Immunology Societies (FOCIS) annual meeting June 24-27, 2015 in San Diego, CA: “Estrogen-mediated TLR8 expression via STAT1 facilitates endogenous miRokine ligand activation by exosomes containing miR-21: a novel innate inflammatory pathway in systemic lupus erythematosus”. Presented during the "Best in Rheumatology 2015" conference session. Recipient of a second consecutive travel award given to selected abstracts to attend this conference.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Nicholas Young, Sphingosine 1-phosphate Receptor Subtype Influence over Glioblastoma Multiforme Pathology
1. INFLUENCE OF SPHINGOSINE 1-PHOSPHATE RECEPTOR SUBTYPES OVER GLIOBLASTOMA MULTIFORME MALIGNANT BEHAVIOR Nicholas Young, Integrated Biomedical Science Graduate Program
25. U118-MG Gelatin Matrigel Well Coating Serum free media Serum free media + 100nm S1P Adhesion Assay * * * * * # #
26.
27. Relationship between G-protein signaling to cellular motility and invasiveness Gi Rac Lamellapodia formation Rho Stress fiber formation G 12/13 PTX Y-27632 ROCK Gi and G12/13 couple to the small GTPases Rho and Rac - results in actin cytoskeleton rearrangements 1. How do the S1P receptor subtypes influence Rho and Rac activation? 2. How does this influence actin cytoskeletal rearrangement? 3. Does Rho/Rac activation influence migratory and invasive response? S1P 2 ?
52. SK inhibitor - + - + - + - + Cntrl S1P 1 S1P 3 S1P 2 SK inhibitor - + - + - + - + Cntrl S1P 1 S1P 3 S1P 2 uPAR GAPDH uPA activity Cntrl * SK activity (pmol/min/mg protein) sphingosine kinase inhibitor and its effects on uPAR expression and uPA activity U-118 MG
53. Cntrl S1P1 Day Cellular viability (%) sphingosine kinase inhibitor and its effects on cellular viability
54. cntrl S1P 1 U-118 MG DMSO SK sicntrl siSK siSK inh A B uPA activity DMSO SK sicntrl siSK siSK inh A B siRNA to SK mimics sphingosine kinase inhibitor in reducing uPA activation
58. 4x 10x 20x 40x SF S1P cAb uPA Ab CCN1 Ab SK inh S1P 1 cellular morphology along the invasive periphery during spheroid invasion
59.
60.
61. SK-1 SK-1 sph S1P S1P S1PR Rac MOTILITY INVASION ERK AKT SURVIVAL GROWTH CCN1 uPA 3 v pro- uPA CCN1 CCN1 CCN1 v v 3 3 (ECM) ADHESION uPAR (Endothelial cell Recruitement) ANGIOGENESIS plasminogen plasmin INVASION uPAR uPAR uPA pro- uPA pro- uPA matriptase CCN1 Ab uPA Ab SK inh
62.
63. X-12 U-87 MG Invasion of human glioma cells into surrounding mouse brain
64. S1P-induced spheroid invasion in neuronal stem cells and X-12 glioma cells Neuronal stem cell line SFME and X-12 glioma cell line were grown in defined media to enrich stem-like cancer cells as neurospheres
70. “ An expert is a man who has made all the mistakes which can be made, in a narrow field.” Niels Bohr (1885-1962) “ Everything should be as simple as it is, but not simpler.” Albert Einstein (1879-1955) “ When you steal from one author, it's plagiarism; if you steal from many, it's research.” Wilson Mizner (1876-1933)
72. cntrl S1P 1 S1P 2 S1P 3 Day Day Day Day Invasive diameter – core diameter ( m) Invasive diameter – core diameter ( m) Invasive diameter – core diameter ( m) Invasive diameter – core diameter ( m) inhibition of spheroid invasiveness with SK inhibitor and uPA/CCN1 ab U-118 MG cells
73. S1P + + + + + + I P Cntrl S1P1 S1P2 I D Cntrl S1P1 S1P2 - plasminogen S1P - + - + - + - + Cntrl S1P 1 S1P 3 S1P 2 uPA activity uPA activity uPA activity is not nonspecific and can be immunoprecipitated